Carvykti sailed through Friday’s adcom, but Abecma got a much rougher ride.

Three recently added trials take Merck & Co’s tally of phase 3 sacituzumab tirumotecan studies to six.

Imetelstat appears headed for approval after its US adcom turns into a damp squib.

First-in-human study initiations include Boundless Bio’s second asset, and an ADC from Tubulis.

The FDA highlights high death rates and questions overall survival for Carvykti and Abecma.

Brutal FDA briefing documents raise questions about the approvability of imetelstat for myelodysplastic syndromes.